A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis.
about
Self-association of human PCSK9 correlates with its LDLR-degrading activityMechanisms and genetic determinants regulating sterol absorption, circulating LDL levels, and sterol elimination: implications for classification and disease riskCandidate gene association resource (CARe): design, methods, and proof of conceptThe E670G SNP in the PCSK9 gene is associated with polygenic hypercholesterolemia in men but not in womenProprotein convertase subtilisin/kexin type 9 (PCSK9) gene is a risk factor of large-vessel atherosclerosis stroke.Longitudinal association of PCSK9 sequence variations with low-density lipoprotein cholesterol levels: the Coronary Artery Risk Development in Young Adults Study.Molecular population genetics of PCSK9: a signature of recent positive selection.What is the impact of PCSK9 rs505151 and rs11591147 polymorphisms on serum lipids level and cardiovascular risk: a meta-analysisGenetic variation at the PCSK9 locus moderately lowers low-density lipoprotein cholesterol levels, but does not significantly lower vascular disease risk in an elderly populationPCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl/Bax-caspase9-caspase3 pathway.Effects of PCSK9 genetic variants on plasma LDL cholesterol levels and risk of premature myocardial infarction in the Italian populationCorrelation of PCSK9 gene polymorphism with cerebral ischemic stroke in Xinjiang Han and Uygur populations.LDLR promoter variant and exon 14 mutation on the same chromosome are associated with an unusually severe FH phenotype and treatment resistance.A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol.Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs.The proprotein convertase subtilisin/kexin type 9 gene E670G polymorphism and serum lipid levels in the Guangxi Bai Ku Yao and Han populationsProprotein convertase subtilisin/kexin type 9 expression is transiently up-regulated in the acute period of myocardial infarction in rat.Both rare and common variants in PCSK9 influence plasma low-density lipoprotein cholesterol level in American IndiansPCSK9 is a critical regulator of the innate immune response and septic shock outcome.The Influence of OLR1 and PCSK9 Gene Polymorphisms on Ischemic Stroke: Evidence from a Meta-AnalysisRelationships between genetic polymorphisms of E670G in PCSK9 gene and coronary artery disease: a meta-analysisThe associations between proprotein convertase subtilisin/kexin type 9 E670G polymorphism and the risk of coronary artery disease and serum lipid levels: a meta-analysis.Genetic variability within the cholesterol lowering pathway and the effectiveness of statins in reducing the risk of MIClinical implications of pharmacogenomics of statin treatment.Several genetic polymorphisms interact with overweight/obesity to influence serum lipid levels.New technologies for delineating and characterizing the lipid exome: prospects for understanding familial combined hyperlipidemia.Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease.Release kinetics of circulating cardiac myosin binding protein-C following cardiac injury.Adaptive genetic variation and heart disease risk.Proprotein Convertase Subtilisin/Kexin type 9, C-Reactive Protein, Coronary Severity, and Outcomes in Patients With Stable Coronary Artery Disease: A Prospective Observational Cohort Study.Regression of atherosclerosis.Proprotein convertases subtilisin/kexin type 9, an enzyme turned escort protein: hepatic and extra hepatic functions.Pharmacogenomics of lipid-lowering therapies.Lipid lowering with PCSK9 inhibitors.Lipid Lowering Therapy and Circulating PCSK9 Concentration.Impact of Pharmacogenetics on Efficacy and Safety of Statin Therapy for Dyslipidemia.Seventeen years of statin pharmacogenetics: a systematic review.Inhibition of PCSK9 does not improve lipopolysaccharide-induced mortality in mice.The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9.Effect of E670G Polymorphism in PCSK9 Gene on the Risk and Severity of Coronary Heart Disease and Ischemic Stroke in a Tunisian Cohort.
P2860
Q24306591-AF97455F-EACA-41FE-A380-302FF1FE7F1EQ27003094-59992F77-D2D3-451B-9231-DC653E5D3BB3Q30432077-D4695CDC-7936-4455-87D5-6E4DF8055462Q33252167-8AF52BCD-A4C4-40D7-B53E-768E9AF7EA5EQ33302900-987D43BB-47BA-4303-8DC1-2DB1FB06AB12Q33605219-0A726F3D-AC59-42DC-B068-C6DCD2BCAD6EQ33743727-F8E4FBB3-15F8-4AA2-BD85-1C8539B447BEQ33792275-CC76A738-2717-4C1A-AE70-3980D7EDB60FQ33848024-5CF07478-08D5-4639-87BF-EAF50829F909Q33994685-CB4A487D-90F9-41B8-81F0-711C74DF23FAQ34188099-7979AD0F-D533-4CFC-9770-0ACEBCA5F78DQ34306545-3CD8E918-7234-4E39-A3E1-73EACEED013AQ34325396-DBFDAA68-E734-45E3-A100-9C2ED8277E52Q34399014-A8F8EC32-2179-4011-A76E-42982B260DB6Q34430377-CE21BCCD-207D-4F51-8353-6E1574F9CCAAQ34559768-F6423ACE-AAED-4F28-B5C3-151185EAA25EQ34789111-E0AAC4A0-0D1C-4D24-8C16-F231DF032BCAQ35055010-B84E631F-299E-4610-B64D-083AE2275E59Q35125516-A8FBB4BD-0C7E-4D4D-B0BE-228CCD5B9F30Q35868554-755550BA-E9A6-4FC9-9EFB-E969384B0CF6Q36182994-A8D2FD1C-806C-454D-A3A0-94276E83F66CQ36292659-608CD4E9-2E98-4879-AE32-C6A698F2F018Q36301394-6E8A7B37-908B-4FC0-BBB6-6066BB83EDF5Q36426816-B534BD61-6EC0-420F-89A7-59B6DE03482CQ36430298-04796ADE-C592-4D81-BF82-1ADBC0C0BAE8Q37331223-08A86ED3-9CE2-4FE5-8858-3C54D469D66AQ37384902-C006AAD2-666D-44AC-96B8-1D6712E02398Q37576160-DC254142-C824-41D8-9C2C-637F933623ACQ37605853-3F3C64B8-3BAD-4D4C-B2E1-B82C09FBA706Q37624278-82942619-7FF5-4060-8696-8C6BF053283DQ38019423-BC17DE8D-7952-416F-B71B-C86A41273249Q38109960-66A9E4C8-8649-4BE9-BBC3-C81DB84BA041Q38112823-C9F1ED4C-8407-4938-AD9F-D273DEE3F2D0Q38222649-4FE5A8BC-AFDD-409F-8A00-A80274A91926Q38643197-70715A44-13CF-4A1A-A816-75B494150E7AQ38663481-47D264EA-9F8B-42A5-8B50-CB8AE1C1A826Q38670109-678F5F08-44AB-4268-8B68-CA4E6EBA9AE5Q38733149-816B25AA-61EA-4BDB-BACF-0EFCE897528CQ39030028-332BECB8-BA33-4923-9B97-774AF54C742DQ39470591-FCD119F6-C630-4D06-BA4A-B4962E921A7C
P2860
A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis.
description
2005 nî lūn-bûn
@nan
2005 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
name
A common PCSK9 haplotype, enco ...... y of coronary atherosclerosis.
@ast
A common PCSK9 haplotype, enco ...... y of coronary atherosclerosis.
@en
A common PCSK9 haplotype, enco ...... y of coronary atherosclerosis.
@nl
type
label
A common PCSK9 haplotype, enco ...... y of coronary atherosclerosis.
@ast
A common PCSK9 haplotype, enco ...... y of coronary atherosclerosis.
@en
A common PCSK9 haplotype, enco ...... y of coronary atherosclerosis.
@nl
prefLabel
A common PCSK9 haplotype, enco ...... y of coronary atherosclerosis.
@ast
A common PCSK9 haplotype, enco ...... y of coronary atherosclerosis.
@en
A common PCSK9 haplotype, enco ...... y of coronary atherosclerosis.
@nl
P2093
P2860
P921
P1476
A common PCSK9 haplotype, enco ...... y of coronary atherosclerosis.
@en
P2093
Ali J Marian
Antonio M Gotto
Christie M Ballantyne
James T Willerson
Suet N Chen
P2860
P304
P356
10.1016/J.JACC.2005.01.051
P407
P577
2005-04-21T00:00:00Z